Multimodal iron oxide (Fe3O4)-saturated lactoferrin nanocapsules as nanotheranostics for real-time imaging and breast cancer therapy of claudin-low, triple-negative (ER-/PR-/HER2-)

被引:36
|
作者
Kanwar, Jagat R. [1 ]
Kamalapuram, Sishir K. [1 ]
Krishnakumar, Subramanian [2 ,3 ]
Kanwar, Rupinder K. [1 ]
机构
[1] Deakin Univ, Fac Hlth, Sch Med SoM,Ctr Mol & Med Res C MMR, Nanomed Lab Immunol & Mol Biomed Res LIMBR, Waurn Ponds, Vic 3217, Australia
[2] Vis Res Fdn, Stem Cell Lab, L&T Ophthalm Pathol Dept, Chennai, Tamil Nadu, India
[3] Vis Res Fdn, Nanobiotechnol Lab, Chennai, Tamil Nadu, India
基金
英国医学研究理事会;
关键词
apoptosis; bovine lactoferrin; iron metabolism; multimodal imaging; nanotheranostic; MAGNETIC NANOPARTICULATE PROBES; DRUG-DELIVERY; IN-VIVO; TARGETED DELIVERY; CELLS; APOPTOSIS; MRI; SURFACE; NANOCARRIERS; TRANSFERRIN;
D O I
10.2217/nnm.15.199
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Aim: To unravel the multimodal nanotheranostic ability of Fe3O4-saturated bovine lactoferrin nanocapsules (FebLfNCs) in claudin-low, triple-negative breast cancer model. Materials & methods: Xenograft study was performed to examine biocompatibility, antitumor efficacy and multimodal nanotheranostic action in combination with near-infrared live mice imaging. Results: FebLf NCs exhibited a size range of 80 nm +/- 5 nm with observed superparamagnetism. FebLf NCs successfully internalized into breast cancer cells through receptor-mediated endocytosis and induced apoptosis through the downregulation of inhibitor of apoptosis survivin and livin proteins. Investigations revealed a remarkable biocompatibility, anticancer efficacy of the FebLf NCs. Near-infrared imaging observations confirmed selective localization of multimodal FebLf NCs at the tumor site and lead to time-dependent reduction of tumor growth. Conclusion: FebLf NCs can be safe, biocompatible nanotheranostic approach for real-time imaging and monitoring the effect of drugs in real time and have potentials in future clinical trials.
引用
收藏
页码:249 / 268
页数:20
相关论文
共 3 条
  • [1] Real-world clinical and economic burden associated with hospitalization in metastatic triple-negative (ER-/PR-/HER2-) breast cancer.
    Tan, Amie
    Han, Xu
    Near, Aimee
    Tse, Jenny
    Preger, Luciana
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts)
    Delaloge, S.
    Tedesco, K. L.
    Blum, J.
    Goncalves, A.
    Lubinski, J.
    Efrat, N.
    Osborne, C.
    Lebedinsky, C.
    Tercero, J. C.
    Holmes, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] A Multifunctional, Highly Biocompatible, and Double-Triggering Caramelized Nanotheranostic System Loaded with Fe3O4 and DOX for Combined Chemo-Photothermal Therapy and Real-Time Magnetic Resonance Imaging Monitoring of Triple Negative Breast Cancer
    Wang, Fangqing
    Li, Nianlu
    Wang, Wenbo
    Ma, Long
    Sun, Yaru
    Wang, Hong
    Zhan, Jinhua
    Yu, Dexin
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2023, 18 : 881 - 897